JP2018508774A - 非アルコール性脂肪性肝疾患を特定するための方法及び組成物 - Google Patents
非アルコール性脂肪性肝疾患を特定するための方法及び組成物 Download PDFInfo
- Publication number
- JP2018508774A JP2018508774A JP2017541920A JP2017541920A JP2018508774A JP 2018508774 A JP2018508774 A JP 2018508774A JP 2017541920 A JP2017541920 A JP 2017541920A JP 2017541920 A JP2017541920 A JP 2017541920A JP 2018508774 A JP2018508774 A JP 2018508774A
- Authority
- JP
- Japan
- Prior art keywords
- eicosanoid
- nash
- subject
- sample
- nafl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
- G01N2800/7085—Lipogenesis or lipolysis, e.g. fatty acid metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本出願は、参照により本明細書に組み込まれる2015年2月13日出願の米国仮出願第62/116,108号の優先権を主張するものである。
Claims (24)
- 対象における非アルコール性脂肪性肝炎(NASH)を非アルコール性脂肪肝(NAFL)と区別する方法であって、
(a)対象から生物試料を得るステップ、
(b)試料をアルカリ溶液で処理してエステル化エイコサノイドを放出させ、エイコサノイドを回収するステップ、及び、
(c)対象から得られた生物試料中の少なくとも1種のエステル化エイコサノイドのレベルをNAFL対象から得られた対照試料と比較するステップを含み、対象から得られた試料中の少なくとも1種のエイコサノイドの、対照と比較したレベルの差がNASHを示す、上記方法。 - (b)で得られるエイコサノイドが、60%超で回収されたエイコサノイドである、請求項1に記載の方法。
- エイコサノイドが、8-HETrE及び15-HETrEからなる群から選択される、請求項1又は2に記載の方法。
- 生物試料が、血液、血漿及び血清からなる群から選択される、請求項1に記載の方法。
- アルカリ処理の前にブチル化ヒドロキシトルエン(BHT)を添加するステップをさらに含む、請求項1に記載の方法。
- アルカリ溶液が水性水酸化カリウム(KOH)である、請求項1に記載の方法。
- 約0.6〜0.7M KOHが使用される、請求項6に記載の方法。
- 約2.5mMのBHTが使用される、請求項5に記載の方法。
- 対象から得られた試料中の少なくとも1種のエイコサノイドの、対照と比較したレベルの増加がNASHを示す、請求項3に記載の方法。
- 試料中のオメガ-3脂肪酸DHA及び/又は17-HDoHEのレベルを測定するステップをさらに含み、対照と比較した増加がNASHを示す、請求項1に記載の方法。
- エイコサノイドが液体クロマトグラフィーにより測定される、請求項1に記載の方法。
- 脂肪酸がガスクロマトグラフィー質量分析法により測定される、請求項10に記載の方法。
- 対象における非アルコール性脂肪性肝炎(NASH)を非アルコール性脂肪肝(NAFL)と区別する方法であって、
(a)対象から生物試料を得るステップ、
(b)試料をアルカリ溶液で処理するステップ、
(c)処理された試料からエイコサノイド及び脂肪酸を回収するステップ、並びに、
(d)対象から得られた生物試料中の少なくとも1種のバイオマーカーレベルを、NAFLであることが分かっている対照試料と比較するステップを含み、対象から得られた試料中の少なくとも1種のバイオマーカーの、対照と比較したレベルの増加がNASHを示し、さらに、バイオマーカーが8-HETrE、15-HETrE、DHA、17-HDoHE及びこれらの任意の組合せからなる群から選択される、上記方法。 - エイコサノイドが、60%超で回収される、請求項13に記載の方法。
- 少なくとも1種のバイオマーカーが、8-HETrE又は15-HETrEを含む、請求項13に記載の方法。
- 生物試料が、血液、血漿及び血清からなる群から選択される、請求項13に記載の方法。
- アルカリ処理の前にブチル化ヒドロキシトルエン(BHT)を添加するステップをさらに含む、請求項31に記載の方法。
- アルカリ溶液が、水性水酸化カリウム(KOH)である、請求項13に記載の方法。
- 約0.6〜0.7M KOHが使用される、請求項18に記載の方法。
- 約2.5mM BHTが使用される、請求項17に記載の方法。
- 試料中のオメガ-3脂肪酸DHA及び/又は17-HDoHEのレベルを測定するステップをさらに含み、対照と比較した増加がNASHを示す、請求項15に記載の方法。
- エイコサノイドが液体クロマトグラフィーにより測定される、請求項13に記載の方法。
- 試料中の脂肪酸が、ガスクロマトグラフィー質量分析法により測定される、請求項13に記載の方法。
- 5-HETE、8-HETE、11-HETE、15-HETE、13-HODE、9-oxoODE及びこれらの任意の組合せからなる群から選択される炎症誘発性エイコサノイドのレベルを測定するステップをさらに含み、NAFL対照より低い上記のいずれかのレベルがNASHを示す、請求項13に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562116108P | 2015-02-13 | 2015-02-13 | |
US62/116,108 | 2015-02-13 | ||
PCT/US2016/017822 WO2016130961A1 (en) | 2015-02-13 | 2016-02-12 | Methods and compositions for identifying non-alcoholic fatty liver disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018508774A true JP2018508774A (ja) | 2018-03-29 |
JP6783239B2 JP6783239B2 (ja) | 2020-11-11 |
Family
ID=56615114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017541920A Active JP6783239B2 (ja) | 2015-02-13 | 2016-02-12 | 非アルコール性脂肪性肝疾患を特定するための方法及び組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11105823B2 (ja) |
EP (1) | EP3256860B1 (ja) |
JP (1) | JP6783239B2 (ja) |
KR (1) | KR102510365B1 (ja) |
CN (1) | CN107407683B (ja) |
AU (1) | AU2016219050B2 (ja) |
CA (1) | CA2975893C (ja) |
WO (1) | WO2016130961A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021157631A1 (ja) * | 2020-02-04 | 2021-08-12 | デンカ株式会社 | 非アルコール性脂肪肝炎の検出を補助する方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3461485A1 (en) * | 2017-09-28 | 2019-04-03 | Dr. Falk Pharma Gmbh | Use of nor-ursodeoxycholic acid for reducing liver fat |
JP7370599B2 (ja) * | 2017-10-06 | 2023-10-30 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 老化細胞のためのバイオマーカー |
GB201802123D0 (en) * | 2018-02-09 | 2018-03-28 | Metabolomic Diagnostics Ltd | A method of processomg a biological sample |
WO2020073000A1 (en) * | 2018-10-05 | 2020-04-09 | The Regents Of The University Ofcalifornia | Methods and compositions for determination of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) |
CN115876935B (zh) * | 2022-12-29 | 2023-11-14 | 大连博源医学科技有限公司 | 一种用于检测血液中11-脱氢血栓烷b2的液相色谱-串联质谱方法和试剂盒 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527438T3 (es) * | 2006-08-08 | 2015-01-26 | Metabolon, Inc. | Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos |
US9060981B2 (en) | 2009-10-16 | 2015-06-23 | Mochida Pharmaceutical Co., Ltd. | Marker associated with non-alcoholic steatohepatitis |
US20130056630A1 (en) * | 2010-05-03 | 2013-03-07 | The Cleveland Clinic Foundation | Detection and monitoring of nonalcoholic fatty liver disease |
EP2863227B1 (en) | 2010-06-10 | 2017-09-27 | Metanomics Health GmbH | Means and methods for metabolic differentiation of non-alcoholic steatohepatitis from liver disease |
KR102258677B1 (ko) | 2013-12-10 | 2021-06-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 간 질환의 감별 진단 |
-
2016
- 2016-02-12 KR KR1020177025260A patent/KR102510365B1/ko active IP Right Grant
- 2016-02-12 US US15/550,706 patent/US11105823B2/en active Active
- 2016-02-12 EP EP16749993.8A patent/EP3256860B1/en active Active
- 2016-02-12 JP JP2017541920A patent/JP6783239B2/ja active Active
- 2016-02-12 CN CN201680016724.2A patent/CN107407683B/zh active Active
- 2016-02-12 CA CA2975893A patent/CA2975893C/en active Active
- 2016-02-12 WO PCT/US2016/017822 patent/WO2016130961A1/en active Application Filing
- 2016-02-12 AU AU2016219050A patent/AU2016219050B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021157631A1 (ja) * | 2020-02-04 | 2021-08-12 | デンカ株式会社 | 非アルコール性脂肪肝炎の検出を補助する方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2016219050B2 (en) | 2022-05-19 |
CA2975893A1 (en) | 2016-08-18 |
US11105823B2 (en) | 2021-08-31 |
WO2016130961A1 (en) | 2016-08-18 |
JP6783239B2 (ja) | 2020-11-11 |
KR102510365B1 (ko) | 2023-03-15 |
CN107407683A (zh) | 2017-11-28 |
EP3256860A4 (en) | 2018-07-04 |
EP3256860A1 (en) | 2017-12-20 |
CN107407683B (zh) | 2020-09-11 |
US20180031585A1 (en) | 2018-02-01 |
EP3256860B1 (en) | 2022-04-20 |
AU2016219050A1 (en) | 2017-08-24 |
CA2975893C (en) | 2023-03-14 |
KR20170116110A (ko) | 2017-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6783239B2 (ja) | 非アルコール性脂肪性肝疾患を特定するための方法及び組成物 | |
Niki | Biomarkers of lipid peroxidation in clinical material | |
Sterz et al. | A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids | |
Vigor et al. | Non-enzymatic lipid oxidation products in biological systems: assessment of the metabolites from polyunsaturated fatty acids | |
Meagher et al. | Alcohol-induced generation of lipid peroxidation products in humans | |
Liu et al. | Ex vivo oxidation in tissue and plasma assays of hydroxyoctadecadienoates: Z, E/E, E stereoisomer ratios | |
Murphy et al. | Analysis of nonvolatile lipids by mass spectrometry | |
JP6680677B2 (ja) | 肝疾患の鑑別診断 | |
Jonasdottir et al. | Effects of anticoagulants and storage conditions on clinical oxylipid levels in human plasma | |
Lefils-Lacourtablaise et al. | The eicosapentaenoic acid metabolite 15-deoxy-δ12, 14-prostaglandin J3 increases adiponectin secretion by adipocytes partly via a PPARγ-dependent mechanism | |
Yoshida et al. | Chemistry of lipid peroxidation products and their use as biomarkers in early detection of diseases | |
Zhang et al. | Characterizing plasma phospholipid fatty acid profiles of polycystic ovary syndrome patients with and without insulin resistance using GC–MS and chemometrics approach | |
Lee et al. | Assessment of isoprostanes in human plasma: technical considerations and the use of mass spectrometry | |
Leung et al. | Current development in non-enzymatic lipid peroxidation products, isoprostanoids and isofuranoids, in novel biological samples | |
Liu et al. | 11-Oxoeicosatetraenoic acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative eicosanoid | |
Langhorst et al. | Determination of F2-isoprostanes in urine by online solid phase extraction coupled to liquid chromatography with tandem mass spectrometry | |
Yin | New techniques to detect oxidative stress markers: mass spectrometry-based methods to detect isoprostanes as the gold standard for oxidative stress in vivo | |
Larose et al. | F2-isoprostanes are correlated with trans fatty acids in the plasma of pregnant women | |
Kathir et al. | Equivalent lipid oxidation profiles in advanced atherosclerotic lesions of carotid endarterectomy plaques obtained from symptomatic type 2 diabetic and nondiabetic subjects | |
Nishiokada et al. | Changes of hepatic lipid mediators associated with intake of high-fat diet for 12 weeks in endotoxemic rats using LC-ESI-MS/MS | |
Camunas-Alberca et al. | The role of oxylipins and their validation as biomarkers in the clinical context | |
Miyoshi et al. | Effect of oral tributyrin treatment on lipid mediator profiles in endotoxin-induced hepatic injury | |
WO2020073000A1 (en) | Methods and compositions for determination of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) | |
JP2007176918A (ja) | 有機酸のアルキルエステル化方法及びキット | |
Onozato et al. | Determination of sex-based differences in serum γ-linoleic acid and dihomo-γ-linoleic acid using gas chromatography–mass spectrometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20181012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181012 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181219 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200508 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201021 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6783239 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |